Charles River Laboratories International Inc

NYSE: CRL
$227.81
-$11.62 (-4.9%)
Closing price April 25, 2024
Charles River Laboratories International Inc is a global provider of essential services to the pharmaceutical and biotechnology industries. With a focus on advancing the drug discovery and development process, the company offers a comprehensive suite of services including research models, preclinical testing, and safety assessment. Its operations span across the United States, Europe, Canada, and the Asia Pacific, supporting clients from early-stage research to manufacturing solutions. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories is dedicated to helping its clients bring new therapies and medicines to the market efficiently.
The top analyst upgrades, downgrades and other research calls from Tuesday include Applied Materials, BioCryst, Costco, Generac, Goodyear, Intel, Microsoft and Netflix.
The top analyst upgrades, downgrades and other research calls from Monday include Apple, BHP Billiton, CBS, Eli Lilly, GE, Halliburton, IBM, Schlumberger and Verizon.
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
The contract research organizations, or CROs, may offer a lot of value as companies look to bring in help from the outside in drug studies and development.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Coeur Mining, Laredo Petroleum, Marathon Oil, Nike and Statoil.
In a new research report, Jefferies analysts focus in on three blue chips stocks rated Buy that they feel have the potential to beat current second-quarter earnings expectations.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Broadcom, Caterpillar, Sirius XM, Newmont, Palo Alto, Perrigo, Sarepta and Xerox.
Monday’s top analyst upgrades, downgrades and initiations include EMC, Goldman Sachs, Linn Energy, MGIC, Marvell Technology and NetApp.
Credit Suisse assumed coverage with handy upside in the CRO leaders, and on average the firm is calling for upside of about 15%.
The analysts at Cowen have calculated the buys and sells in the NYSE Arca Biotechnology Index based on the holdings in the First Trust Biotechnology ETF.
Friday's top analyst upgrades, downgrades and initiations include AT&T, Costco, Gap, Intercontinental Exchange, Rackspace, Sprint, Verizon Communications and Weatherford International.
The Jefferies top U.S. growth picks for this week run the gamut, and all are suitable for more aggressive accounts.
Tuesday's top analyst upgrades and downgrades include American Express, BIND Therapeutics, Devon Energy, General Motors, Novavax and Toyota.
Source: ThinkstockCredit Suisse has initiated research coverage on the so-called contract services organizations, or CROs. The firm’s Jeffrey Bailin started the sector with a Market Weight rating,...
These are the top analyst upgrades, downgrades and initiations from select Wall Street research calls on Tuesday, June 18, 2013. They include Intuitive Surgical, Palo Alto Networks and T-Mobile US.